Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
- Matt E. Kalaycio(corresponding author),
- Manisha Kukreja,
- Ann E. Woolfrey,
- Jeffrey Szer,
- ,
- Richard T. Maziarz
- Cleveland Clinic Foundation,
- Medical College of Wisconsin,
- Fred Hutchinson Cancer Research Center,
- Royal Melbourne Hospital,
- University of Texas MD Anderson Cancer Center,
- Oregon Health and Science University
Scholary Output:
Contribution to journal
Article
Peer-review
Open access
Abstract
The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 543-547 (5 pages)Journal (Volume, Issue Number)
Biology of Blood and Marrow Transplantation (Volume 16, Issue 4)Publication milestones
- Published - 04/2010
Publication status
Published - 04/2010
ISSN
1083-8791Publication IDs
- Scopus: 77949271439
- PubMed: 19961946
- ORCID: /0000-0002-8636-1071/work/68887826
Publication metrics
Metrics
SciVal
citations
26
Fractional count
1
Fractional count
0.06
Fractional count
15
Fractional count
0.94
Fractional count
1
Fractional count
1
SciVal
FWCI
0.59
SciVal
Author count
16
SciVal
Paper percentile
81
PlumX, opens in new tab
Citation count
38
Captures
36
Funding Details
Financial disclosure: CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI ; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS) ; 2 grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB ; Aetna ; American Society for Blood and Marrow Transplantation ; Amgen, Inc. ; anonymous donation to the Medical College of Wisconsin ; Association of Medical Microbiology and Infectious Disease Canada ; Astellas Pharma US, Inc. ; Baxter International, Inc. ; Bayer HealthCare Pharmaceuticals ; BloodCenter of Wisconsin ; Blue Cross and Blue Shield Association ; Bone Marrow Foundation ; Canadian Blood and Marrow Transplant Group ; Celgene Corporation ; CellGenix, GmbH ; Centers for Disease Control and Prevention ; ClinImmune Labs ; CTI Clinical Trial and Consulting Services ; Cubist Pharmaceuticals ; Cylex Inc. ; CytoTherm ; DOR BioPharma, Inc. ; Dynal Biotech , an Invitrogen Company ; Enzon Pharmaceuticals, Inc. ; European Group for Blood and Marrow Transplantation ; Gambro BCT, Inc. ; Gamida Cell, Ltd. ; Genzyme Corporation ; Histogenetics, Inc. ; HKS Medical Information Systems ; Hospira, Inc. ; Infectious Diseases Society of America ; Kiadis Pharma ; Kirin Brewery Co., Ltd. ; Merck & Company ; The Medical College of Wisconsin ; MGI Pharma, Inc. ; Michigan Community Blood Centers ; Millennium Pharmaceuticals, Inc. ; Miller Pharmacal Group ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Nature Publishing Group ; New York Blood Center ; Novartis Oncology ; Oncology Nursing Society ; Osiris Therapeutics, Inc. ; Otsuka Pharmaceutical Development & Commercialization, Inc. ; Pall Life Sciences ; PDL BioPharma, Inc ; Pfizer Inc ; Pharmion Corporation ; Saladax Biomedical, Inc. ; Schering Plough Corporation ; Society for Healthcare Epidemiology of America ; StemCyte, Inc. ; StemSoft Software, Inc. ; Sysmex ; Teva Pharmaceutical Industries ; The Marrow Foundation ; THERAKOS, Inc. ; Vidacare Corporation ; Vion Pharmaceuticals, Inc. ; ViraCor Laboratories ; ViroPharma, Inc. ; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.
FundersFunding numbers
Amgen, Inc.
-Baxter International, Inc.
-CIBMTR
U24-CA76518
Cubist Pharmaceuticals
-Cylex Inc.
-Enzon Pharmaceuticals, Inc.
-European Group for Blood
-HRSA/DHHS
N00014-06-1-0704, N00014-08-1-0058
Invitrogen Company
-MGI Pharma, Inc.
-Michigan Community Blood Centers
-Nature Publishing Group
-Saladax Biomedical, Inc
-Schering Plough Corporation
-Society for Healthcare Epidemiology of America
-ONR
-NHLBI
U01HL069294
NCI
-NIAID
HHSH234200637015C
HRSA
-Teva Pharmaceutical Industries Ltd.
-AABB
-ASBMT
-Arrow Bone Marrow Transplant Foundation
-AMMI Canada
-BHC
-Astellas Pharma
-